Hexavest’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
$8.58M Buy
144,934
+29,611
+26% +$1.95M 0.52% 60
2021
Q2
$7.71M Sell
115,323
-121,209
-51% -$7.9M 0.38% 90
2021
Q1
$14.9M Sell
236,532
-59,473
-20% -$3.7M 0.66% 42
2020
Q4
$18.4M Sell
296,005
-117,058
-28% -$7.2M 0.69% 43
2020
Q3
$24.9M Sell
413,063
-466,343
-53% -$28.1M 0.67% 45
2020
Q2
$51.7M Sell
879,406
-126,915
-13% -$7.59M 1.2% 18
2020
Q1
$56.1M Sell
1,006,321
-46,184
-4% -$2.82M 0.98% 22
2019
Q4
$67.6M Buy
+1,052,505
New +$60.3M 0.82% 33
2019
Q3
Sell
-4,930
Closed -$224K 513
2019
Q2
$224K Hold
4,930
﹤0.01% 283
2019
Q1
$235K Sell
4,930
-908,197
-99% -$45.2M ﹤0.01% 258
2018
Q4
$47.5M Sell
913,127
-891,813
-49% -$47.9M 0.69% 45
2018
Q3
$112M Buy
1,804,940
+1,011,623
+128% +$60M 1.43% 14
2018
Q2
$43.9M Sell
793,317
-3,063
-0.4% -$165K 0.57% 61
2018
Q1
$50.4M Sell
796,380
-733,658
-48% -$47.2M 0.63% 52
2017
Q4
$93.8M Buy
1,530,038
+33,562
+2% +$2.1M 1.07% 17
2017
Q3
$95.4M Buy
1,496,476
+33,485
+2% +$1.96M 1.17% 17
2017
Q2
$81.5M Sell
1,462,991
-61,502
-4% -$3.35M 1.06% 19
2017
Q1
$82.9M Buy
1,524,493
+51,529
+3% +$2.83M 0.99% 21
2016
Q4
$86.1M Buy
1,472,964
+790,752
+116% +$43.2M 1.18% 20
2016
Q3
$36.8M Buy
682,212
+671,584
+6,319% +$43.1M 0.63% 51
2016
Q2
$782K Hold
10,628
0.01% 258
2016
Q1
$679K Hold
10,628
0.01% 258
2015
Q4
$731K Hold
10,628
0.01% 249
2015
Q3
$629K Hold
10,628
0.01% 246
2015
Q2
$707K Hold
10,628
0.01% 253
2015
Q1
$686K Hold
10,628
0.01% 238
2014
Q4
$627K Hold
10,628
0.01% 238
2014
Q3
$544K Hold
10,628
0.01% 253
2014
Q2
$516K Hold
10,628
0.01% 254
2014
Q1
$552K Hold
10,628
0.01% 248
2013
Q4
$565K Sell
10,628
-546,845
-98% -$27.9M 0.01% 261
2013
Q3
$25.8M Sell
557,473
-15,076
-3% -$662K 0.39% 79
2013
Q2
$25.6M Buy
+572,549
New +$24.9M 0.44% 67

Other funds holding BMY

Hexavest's BMY Position: Q3 2021 in Review

Hexavest increased its Bristol-Myers Squibb (BMY) stake by 26% in Q3 2021, buying an estimated $1.95M and bringing the position to 144,934 shares worth $8.58M. The position accounts for 0.52% of the portfolio, ranked #60.

Hexavest first reported a position in BMY in Q2 2013 and has held it in 33 quarters since. The position peaked at $112M in Q3 2018. 2,292 funds tracked by Wall St. Rank hold BMY as of Q3 2021.

  • Hexavest held 144,934 shares of Bristol-Myers Squibb worth $8.58M as of Q3 2021.
  • Hexavest bought 29,611 Bristol-Myers Squibb shares in Q3 2021, an estimated $1.95M.
  • Bristol-Myers Squibb made up 0.52% of Hexavest's portfolio in Q3 2021, its #60 holding.
  • Hexavest first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 33 quarters since.
  • Hexavest's Bristol-Myers Squibb position peaked at $112M in Q3 2018.
  • 2,292 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2021.

Based on Hexavest's 13F filing for Q3 2021, filed 27 Oct 2021.